OrganiGram Holdings Inc.

TSX:OGI.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.96 -1.43%

-$0.02 today

Market cap
$135.37M
Beta
1.84
P/E (TTM)
-7.2
EPS (TTM)
-$0.19
52W Low $1.37High $3.09

Volume 0.54M

Average 0.19M

OGI.TO EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

OrganiGram Holdings Inc.TSX: OGI.TO

EBITDA · Q2 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q2 FY2026 EBITDA was -CA$28.01M, compared with -CA$2.74M a year earlier. Trailing-twelve-month EBITDA was -CA$40.84M.

Context

  • EBITDA amounted to 7.9% of revenue in FY2025, down 6.8 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of CA$138.34M (+773.1%) for the fiscal year ending Sep 2026, a step up from the +12.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$28.01M-1893.0% QoQ
Last fiscal yearSep 2025
-CA$20.55M+12.9% YoY
LTMMar 2026
-CA$40.84M-681.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-920.7%+246.7%+1167.4 pp
1 year+12.9%+773.1%+760.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

CAD · from the income statement

Latest · FY2025
(20.55M) CAD
Year-over-year change
+12.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How OGI.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -681.4% is the lowest of 10, against a peer median of +45.8%.
  • EBITDA amounts to 14.9% of revenue for OGI.TO, versus a peer median of 23.9%.
OGI.TO Competitors
EBITDA for OGI.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DR.TOMedical Facilities CorporationLTM Mar 2026$75.52M USD-3.6%+5.1%24.7%
TSND.TOTerrAscend Corp.LTM Mar 2026$60.46M USD+510.4%—23.1%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$49.15M CAD+45.8%—31.0%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$25.12M USD+96.0%+26.0%49.3%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$17.79M USD+21.8%+0.0%31.9%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$9.82M CAD-80.9%—3.1%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026-$5.36M USD+48.2%—10.5%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026-CA$40.84M CAD-681.4%—14.9%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026-$44.63M USD-141.2%——
WEED.TOCanopy Growth CorporationLTM Mar 2026-CA$63.48M CAD+86.8%—20.4%
Peer median (excluding OGI.TO) —+45.8%+5.1%23.9%

Competitors are the stored peer set for OGI.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue79.16M145.81M149.21M159.84M259.18M
Cost of Revenue107.56M114.24M114.13M112.32M249.67M
Gross Profit(28.4M)31.57M35.07M47.52M9.51M
Gross Margin-35.9%21.7%23.5%29.7%3.7%
Research & Development3.45M5.96M12.19M11.2M10.95M
Selling, General & Admin46.52M59.21M71.68M68.14M86.88M
Operating Expenses63.42M70.32M277.81M83.2M97.82M
Depreciation & Amortization31.03M24.91M24.17M12.08M17.98M
EBITDA(95.59M)10.97M(207.62M)(23.59M)(20.55M)
EBITDA Margin-120.8%7.5%-139.2%-14.8%-7.9%
Operating Income(91.82M)(43.15M)(242.74M)(35.67M)(88.31M)
Operating Margin-116.0%-29.6%-162.7%-22.3%-34.1%
Interest Income003.69M3.31M1.15M
Interest Expense2.96M429K277.85K00
Other Income / Expenses(38.88M)28.78M9.74M(9.77M)49.78M
Income Before Tax(130.7M)(14.37M)(233M)(45.44M)(38.53M)
Pre-Tax Margin-165.1%-9.9%-156.2%-28.4%-14.9%
Income Tax Expense0(88K)(3.52M)(5.28M)(13.77M)
Net Income(130.7M)(14.28M)(229.48M)(45.44M)(24.76M)
Net Margin-165.1%-9.8%-153.8%-28.4%-9.6%
EPS (Basic)(2.04)(0.18)(2.82)(0.48)(0.19)
EPS (Diluted)(2.04)(0.18)(2.82)(0.48)(0.19)
Weighted Avg Shares64.03M77.23M81.29M95.29M127.67M
Weighted Avg Shares (Diluted)64.03M77.23M81.29M95.29M127.67M

OrganiGram Holdings Inc.

TSX:OGI.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.